TrialSignal
Clinical trial intelligence report
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03751007
Status
COMPLETED
Phase
Phase 1b/2a
Sponsor
Precigen Actobio T1D, LLC
Executive brief
Investment-Ready Snapshot
The clinical trial assessed the safety and tolerability of AG019, both as a monotherapy and in combination with Teplizumab, in patients with recent-onset Type 1 Diabetes. Conducted by Precigen Actobio T1D, LLC, the study aimed to evaluate different dosing regimens across two age groups (12-17 and 18-40 years).
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03751007
Indication
Diabetes type1
Modality
monoclonal antibody
Target
Type 1 Diabetes (T1D)
Intervention
AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose, AG019 - High Dose
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.